

# Dean Y Maeda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6847647/publications.pdf>

Version: 2024-02-01

28  
papers

2,034  
citations

471509

17  
h-index

501196

28  
g-index

33  
all docs

33  
docs citations

33  
times ranked

3496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effective combinatorial immunotherapy for castration-resistant prostate cancer. <i>Nature</i> , 2017, 543, 728-732.	27.8	403
2	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 559-572.e7.	16.8	353
3	Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain. <i>Journal of Biological Chemistry</i> , 2001, 276, 42639-42644.	3.4	297
4	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. <i>JCI Insight</i> , 2019, 4, .	5.0	168
5	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. <i>Clinical Cancer Research</i> , 2020, 26, 1420-1431.	7.0	151
6	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. <i>JCI Insight</i> , 2019, 4, .	5.0	113
7	Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. <i>Molecular Pharmaceutics</i> , 2004, 1, 40-48.	4.6	110
8	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. <i>Cancer Discovery</i> , 2022, 12, 47-61.	9.4	58
9	Simultaneous inhibition of CXCR1/2, TGF- $\beta$ 2, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. , 2020, 8, e000326.		54
10	N-Arylalkylpiperidines as High-Affinity Sigma-1 and Sigma-2 Receptor Ligands: Phenylpropylamines as Potential Leads for Selective Sigma-2 Agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 497-500.	2.2	30
11	IL-8 signaling does not mediate intra-amniotic LPS-induced inflammation and maturation in preterm fetal lamb lung. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L512-L519.	2.9	30
12	Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8378-8397.	6.4	29
13	Optimization of Bivalent Glutathione S-Transferase Inhibitors by Combinatorial Linker Design. <i>Journal of the American Chemical Society</i> , 2006, 128, 8615-8625.	13.7	23
14	Glutathione S-transferase P1-1 expression modulates sensitivity of human kidney 293 cells to photodynamic therapy with hypericin. <i>Archives of Biochemistry and Biophysics</i> , 2006, 449, 94-103.	3.0	21
15	A sigma-1 receptor selective analogue of BD1008, a potential substitute for (+)-opioids in sigma receptor binding assays. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 17-18.	2.2	20
16	Bivalent inhibitors of glutathione S-transferase: The effect of spacer length on isozyme selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3780-3783.	2.2	20
17	Intestinal Transport of Aminopterin Enantiomers in Dogs and Humans with Psoriasis Is Stereoselective: Evidence for a Mechanism Involving the Proton-Coupled Folate Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 342, 696-708.	2.5	20
18	Synthesis and Evaluation of N,N-Dialkyl Enkephalin-Based Affinity Labels for $\mu$ Opioid Receptors. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3941-3948.	6.4	19

#	ARTICLE	IF	CITATIONS
19	Synthesis and Evaluation of Isothiocyanate-Containing Derivatives of the $\hat{\nu}$ -Opioid Receptor Antagonist Tyr-Tic-Phe-Phe (TIPP) as Potential Affinity Labels for $\hat{\nu}$ -Opioid Receptors. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 5044-5049.	6.4	15
20	Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3793-3797.	2.2	12
21	Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2280-2284.	2.2	12
22	Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. <i>Nature Communications</i> , 2021, 12, 5024.	12.8	11
23	Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. <i>Journal of Pain</i> , 2019, 20, 1218-1235.	1.4	10
24	Desmetramadol Is Identified as a G-Protein Biased $\hat{\mu}$ Opioid Receptor Agonist. <i>Frontiers in Pharmacology</i> , 2019, 10, 1680.	3.5	10
25	Nicotinamide Glycolates Antagonize CXCR2 Activity through an Intracellular Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 145-152.	2.5	9
26	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. <i>Cancers</i> , 2021, 13, 968.	3.7	9
27	Snap-to-it probes: chelate-constrained nucleobase oligomers with enhanced binding specificity. <i>Nucleic Acids Research</i> , 2008, 36, 3522-3530.	14.5	8
28	Studies into the Direct Conversion of Indolomorphinans to their 4-Phenolic Derivatives. <i>Tetrahedron</i> , 2000, 56, 7399-7402.	1.9	4